Amneal Pharmaceuticals, Inc.
AMRX
$11.90
-$0.29-2.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 103.20% | 101.93% | 92.27% | -39.16% | -1,886.83% |
| Total Depreciation and Amortization | 5.94% | 8.93% | 6.19% | 2.96% | -2.80% |
| Total Amortization of Deferred Charges | 67.57% | 126.30% | 199.04% | 321.85% | 199.71% |
| Total Other Non-Cash Items | -4.17% | -43.09% | -46.41% | -44.38% | 27.02% |
| Change in Net Operating Assets | -713.35% | -54.57% | 13.19% | 91.38% | 111.77% |
| Cash from Operations | 4.77% | 39.06% | 52.35% | -14.61% | 67.78% |
| Capital Expenditure | -57.32% | -78.10% | -41.66% | -28.93% | -6.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 40.41% | 40.41% | -- | -- | -- |
| Other Investing Activities | 61.37% | 70.33% | 71.18% | 34.56% | -1,264.55% |
| Cash from Investing | -5.39% | -13.62% | 20.95% | 8.95% | -60.59% |
| Total Debt Issued | 678.78% | -43.34% | -46.14% | -89.01% | 240.67% |
| Total Debt Repaid | -549.98% | 5.53% | -0.12% | 43.70% | -160.19% |
| Issuance of Common Stock | 48.95% | 81.84% | 149.48% | 155.88% | 156.37% |
| Repurchase of Common Stock | -189.39% | -190.42% | -195.71% | -234.40% | -234.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 33.51% | 81.76% | 91.03% | 91.48% | -146.18% |
| Cash from Financing | 67.14% | 4.58% | -2.23% | 0.37% | -87.76% |
| Foreign Exchange rate Adjustments | -3,712.07% | -312.57% | -50.40% | -1,636.92% | 98.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,027.25% | 152.42% | 116.87% | -69.77% | -5,978.17% |